HMDC.F'un PS Oranı emsallerine kıyasla nasıldır?

HMDC.F, Price-To-Sales değerine göre iyi bir değerdir. Eş ortalamaya (3.2x) kıyasla oran (8x).

HMDC.F'nin PS Oranı, US Pharmaceuticals Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

HMDC.F Price-To-Sales Oranı ( 3.2 x) baz alındığında, US Pharmaceuticals sektör ortalamasına ( 2.9 x) kıyasla iyi bir değerdir.

HMDC.F'nin PS Oranı, Adil PS Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PS Oranıdır.

Değerleme analizi için HMDC.F 'in Price-To-Sales Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında HMDC.F 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

HMDC.F ( $3.82 ) [[adil değer]] tahminimizin altında işlem görüyor ( $13.46 )

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Fiyat tahminini göstermek için yeterli veri yok.

HUTCHMED (China) (OTCPK:HMDC.F) - Hisse Senedi Fiyatı, Haberler ve Analizler

HMDC.F Stoklara Genel Bakış

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. Daha fazla detay

HMDC.F temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 71.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 31.13% oranında artması öngörülüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

HUTCHMED (China) Limited Rakipler

Wave Life Sciences

NasdaqGM:WVE

US$2.3b

Tarsus Pharmaceuticals

NasdaqGS:TARS

US$1.8b

Harmony Biosciences Holdings

NasdaqGM:HRMY

US$2.0b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti HUTCHMED (China)
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	UK£3.82
52 Haftanın En Yüksek Seviyesi	UK£3.95
52 Haftanın En Düşük Seviyesi	UK£2.05
Beta	0.65
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	5.97%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	82.54%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	HMDC.F	US Pharmaceuticals	US Pazar
7D	0%	4.2%	2.0%
1Y	6.0%	13.7%	32.4%

Getiri vs. Endüstri: HMDC.F geçen yıl % 13.7 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: HMDC.F geçen yıl % 32.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is HMDC.F's price volatile compared to industry and market?
HMDC.F volatility
HMDC.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: HMDC.F son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: HMDC.F 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	1,990	Wei-Guo Su	www.hutch-med.com

HUTCHMED (China) Limited Temel Bilgiler Özeti

HUTCHMED (China)'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
HMDC.F temel i̇stati̇sti̇kler
Piyasa değeri	US$2.45b
Kazançlar(TTM)	-US$29.42m
Gelir(TTM)	US$757.24m

3.2x

P/S Oranı

-83.3x

F/K Oranı

HMDC.F aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
HMDC.F gelir tablosu (TTM)
Gelir	US$757.24m
Gelir Maliyeti	US$731.89m
Brüt Kâr	US$25.34m
Diğer Giderler	US$54.77m
Kazançlar	-US$29.42m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

Feb 28, 2024

Hisse başına kazanç (EPS)	-0.034
Brüt Marj	3.35%
Net Kâr Marjı	-3.89%
Borç/Özkaynak Oranı	5.0%

HMDC.F uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

HMDC.F Stoklara Genel Bakış

Ödüller

Risk Analizi

HUTCHMED (China) Limited Rakipler

NasdaqGM:WVE

US$2.3b

NasdaqGS:TARS

US$1.8b

NasdaqGM:HRMY

US$2.0b

NasdaqGS:AMPH

US$2.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review

Recent updates

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023

HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China

Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer

HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib

HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

HUTCHMED (China) Limited Temel Bilgiler Özeti

3.2x

-83.3x

Kazanç ve Gelir